AUTHORS
Scott R Goldsmith, MD, Hans C Lee, MD2, Krina Patel Jr, MD, MSc3, Tara K Gregory, MD4, Ajay K Nooka, MD, MPH5, Faith Davies, MD6, Ravi Vij, MD, MBA7, Hira Shaikh, MD8, Indumathy Varadarajan, MD9, Saswati Hazra, PhD10, Kazusa Ishii, MD, MPH11, Steven Wang, MS12, Patricia Pak Yan Cheung, PhD13, Liang Li, PhD14, Melissa Alsina, MD15
AFFILIATIONS
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 Sarah Cannon Research Institute, Nashville, Tennessee, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Colorado Blood Cancer Institute, Denver, Colorado, United States
5 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
6 New York University Langone, New York, New York, United States
7 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
8 University of Iowa Hospital & Clinic, Iowa City, Iowa, United States
9 University of Virginia Health, Charlottesville, Virginia, United States
10 AstraZeneca, South San Francisco, California, United States
11 AstraZeneca, Gaithersburg, Maryland, United States
12 AstraZeneca, Mississauga, Ontario, Canada
13 AstraZeneca, South San Francisco, California, United States
14 AstraZeneca, Gaithersburg, Maryland, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
ABSTRACT
Introduction: AZD0120 is a first-in-class, dual-targeting autologous CAR-T cell therapy directed against BCMA and CD19, manufactured on a next-generation platform to enable rapid production of predominantly naïve/stem cell memory (SCM) and central memory T cell phenotypes. Phase 1 studies have shown a favorable safety profile and promising preliminary efficacy of AZD0120 in relapsed/refractory multiple myeloma (MM). Here we report preliminary phase 1 results from the DURGA-2 study (NCT07073547), which evaluates AZD0120 in high-risk (HR) patients (pts) with newly diagnosed MM (NDMM).
Methods: This phase 1, open-label, single-arm, multicenter study evaluated safety and preliminary efficacy of AZD0120 in pts with HR-NDMM. Eligible pts were aged ≥18 years with a diagnosis of HR NDMM (HR defined as presence of ≥1 of: R-ISS II or III, ≥1 HR cytogenetic features [del(17p), t(4;14), t(14;16), t(14;20), 1q21 amp (≥4 copies), monoallelic del(1p32) with 1q+, biallelic del(1p32), TP53 mutation], extramedullary disease, or IgD or IgE subtype). Pts received physician’s choice standard induction therapy (1–6 cycles) pre-apheresis. Bridging therapy was given at investigator discretion and counted toward a 6-cycle maximum. Following standard Flu/Cy lymphodepletion, pts received AZD0120 at dose level (DL) 1 (1×10⁵ cells/kg) or DL2 (3×10⁵ cells/kg). Lenalidomide maintenance was initiated 2–6 months post-AZD0120 infusion. Primary objectives were safety/tolerability and RP2D determination; secondary objectives included efficacy and cellular kinetics of AZD0120.
Results: As of data cutoff (DCO; April 13, 2026), 27 pts received AZD0120 (DL1 n=3; DL2 n=24); median follow-up from AZD0120 infusion was 6.5 months (range 5.8–7.1) for the DL1 cohort and 1.5 months (range 0–4.4) for DL2. Median age was 64 years (range 42–73), 20 pts (74.1%) had R-ISS II and 7 pts (25.9%) had R-ISS III at initial diagnosis, and 12 pts (44%) had HR cytogenetic abnormalities. Three pts (11.1%) received 1–2 cycles, 13 (48.1%) received 4 cycles, and 11 (40.7%) received 5–6 induction cycles pre-apheresis; 7 pts (25.9%) received bridging therapy. Investigator-assessed best response pre-apheresis was: sCR in 1 pt (3.7%), CR in 1 pt (3.7%), VGPR in 15 pts (55.6%), PR in 6 pts (22.2%), and SD in 4 pts (14.8%). Median time from apheresis to release was 16 days (range 12–34). No dose-limiting toxicities or deaths were reported. Two pts (66.7%) at DL1 and 15 (62.5%) at DL2 experienced treatment-emergent SAEs. TEAEs observed in ≥20% of overall pts were CRS (55.6%) and hematological AEs of neutropenia (48.1%), leukopenia (37.0%), and thrombocytopenia (25.9%). The Gr3 infection rate was 3.7%. Among 19 pts (DL1 n=3; DL2 n=16) with ≥28 days of follow-up post AZD0120 infusion, 14 (73.7%) experienced CRS (Gr1, 13 [68.4%]; Gr3, 1 [5.3%]) and 3 (15.8%) experienced Gr1 ICANS. Median time to onset of CRS and ICANS from CAR-T infusion was 8 days (range 4–22) and 10 days (range 8–10), respectively; median duration of CRS and ICANS was 3 days (range 1–5) and 2 days (range 2–4), respectively. There have been no events of Parkinsonism, motor neuropathies, IEC-HS, IEC-EC, or second primary malignancies. In 18 efficacy evaluable pts (DL1 n=3; DL2 n=15), ORR was 100% (95% CI 81.5–100), including VGPR or better in 17 pts (94.4%; DL1 100%; DL2 93.3%). All responses were ongoing at DCO. Relative to disease status at enrollment pre-apheresis, 14/18 pts (77.8%) experienced deepening response after AZD0120 infusion, including conversion to CR/sCR in 9 pts (50.0%). Robust in vivo CAR-T expansion was observed, with geometric mean Cmax of 59,958 copies/μg gDNA (CV%: 83.3%) at median Tmax of 10 days (range 9–14) and rapid soluble BCMA reduction of over 90% within 2 months. Lenalidomide maintenance was initiated in 7 pts (DL1 n=3; DL2 n=4). Two pts in DL1 discontinued lenalidomide due to AEs (Gr3 peripheral sensory neuropathy; Gr3 neutropenia with subsequent dizziness; both resolved after discontinuation of lenalidomide). In DL2, no lenalidomide-related TEAEs have been reported, with a relatively short duration since starting lenalidomide (median 20.5 days) at DCO.
Conclusions: In this cohort of pts with HR NDMM, consolidation with AZD0120 demonstrated an acceptable safety profile and encouraging efficacy. Longer follow-up will define response durability, late safety, and outcomes with lenalidomide maintenance. Updated efficacy and NGS MRD data will be presented at the annual meeting.
DISCLOSURES
Scott R Goldsmith, MD: BMS - Honoraria; Johnson & Johnson - Honoraria; DAVA Oncology - Honoraria; Bioline - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)